PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30907440-0	2019	Relevance of CYP2B6 and CYP2D6 genotypes to methadone pharmacokinetics and response in the OPAL study.	Methadone	44-53	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	13-19	
30907440-1	2019	AIMS: Our study aimed to evaluate the impacts of the cytochrome P450 (CYP) 2B6-G516T and CYP2D6 genetic polymorphisms on pharmacokinetic and clinical parameters in patients receiving methadone maintenance treatment.	Methadone	183-192	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	53-78	
30907440-4	2019	RESULTS: When comparing the three CYP2B6 genotype groups, the methadone (R)- and (S)-methadone enantiomer concentrations/doses (concentrations relative to doses) were different (P = .029, P = .0019).	Methadone	62-71	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40	
30907440-4	2019	RESULTS: When comparing the three CYP2B6 genotype groups, the methadone (R)- and (S)-methadone enantiomer concentrations/doses (concentrations relative to doses) were different (P = .029, P = .0019).	Methadone	81-94	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	34-40	
30907440-7	2019	CONCLUSION: The genotyping of CYP2B6 G516T could be an interesting tool to explore methadone intervariability.	Methadone	83-92	cytochrome P450 family 2 subfamily B member 6	Homo sapiens	30-36